Abstract
Type I insulin-like growth factor (IGF) receptor (IGF1R) inhibitors are new cancer therapies. Pitts and colleagues used in vitro data to "train" a predictive biomarker for an IGF1R tyrosine kinase inhibitor. Given the complexity of IGF signaling, additional layers of biomarker analysis will likely be needed to develop predictive factors.
Original language | English (US) |
---|---|
Pages (from-to) | 3091-3093 |
Number of pages | 3 |
Journal | Clinical Cancer Research |
Volume | 16 |
Issue number | 12 |
DOIs | |
State | Published - Jun 15 2010 |